Portal de Periódicos da CAPES

An Explanation for the Increasing Incidence of Testis Cancer: Decreasing Age at First Full-Term Pregnancy

1997; Oxford University Press; Volume: 89; Issue: 11 Linguagem: Inglês

10.1093/jnci/89.11.818

1460-2105

Brian E. Henderson, Ronald K. Ross, Mimi C. Yu, Leslie Bernstein,

Sexual Differentiation and Disorders

122,721 alone had fewer vomiting episodes (mean, two versus seven) (P ‫ס‬ .007).Six (86%) of the seven patients who received one dose of CP-122,721 alone as prophylaxis reported no delayed emesis.Acute emesis and delayed emesis were similar among the CP-122,721 doses.No adverse effects of 721 occurred.This trial reports the first use of a substance-P antagonist to prevent cisplatin-induced emesis.The most dramatic finding was the prevention of delayed vomiting in 83% of the patients given a single prophylactic dose of CP-122,721.Only 17% of previously treated individuals had no delayed emesis in their prior course (P ‫ס‬ .006).This observation that NK 1 receptor blockade prevents delayed emesis suggests that substance P may, in part, mediate this reflex.In patients receiving CP-122,721 alone as prophylaxis for acute cisplatininduced emesis, vomiting was lessened compared with historical data (7), showing activity against acute emesis.For patients who had experienced acute emesis with a serotonin antagonist and dexamethasone in prior cycles, control during a subsequent cycle with CP-122,721 did not decline as expected (12).These data suggest that NK 1 antagonists may provide additive acute control.Further study of NK 1 receptor antagonists provides a singular opportunity to improve our understanding and control of emesis.